Phage Therapy Market: Market Size & Forecast 2026

The global phage therapy market focuses on developing and commercializing bacteriophage-based treatments for bacterial infections, particularly those resistant to conventional antibiotics. With a 2025 valuation around $0.49 billion, the sector is experiencing steady growth as medical institutions, pharmaceutical companies, and government agencies invest in phage research and infrastructure. The market includes both personalized phage cocktails tailored to individual patients and standardized phage products targeting common pathogens.

• •Phage therapy leverages naturally occurring viruses that selectively infect and lyse specific bacterial strains, offering precision targeting with minimal disruption to beneficial microbiota
• •The market covers human therapeutics, veterinary applications, agricultural uses, and phage-based diagnostic tools for rapid pathogen identification
• •Currently transitioning from compassionate-use frameworks and niche clinics toward broader regulatory-approved commercial availability

The escalating global crisis of antibiotic-resistant infections is the primary force propelling market expansion, with drug-resistant bacteria responsible for well over a million deaths annually worldwide. Phage therapy offers a targeted alternative that can be customized to specific bacterial strains, making it particularly valuable for treating multidrug-resistant organisms in hospitals and long-term care settings. Increased regulatory engagement and clinical trial activity, particularly in the United States and Europe, are validating phage therapy as a legitimate clinical modality and attracting significant investment from both pharmaceutical companies and biotech investors.

• •Rising prevalence of infections resistant to multiple antibiotic classes, including carbapenem-resistant Enterobacteriaceae and methicillin-resistant Staphylococcus aureus, creates urgent clinical demand
• •Advancing regulatory pathways, including FDA guidance on investigational new drug applications for phage products and European Medicines Agency frameworks, are lowering barriers to clinical development
• •Growing investment from major pharmaceutical companies and venture capital is accelerating product development and manufacturing scale-up

The market is segmented into therapeutic applications, diagnostics, and agricultural and food-safety uses, with human therapeutics representing the largest and fastest-growing segment. Geographically, North America and Europe dominate due to advanced research institutions, regulatory frameworks supporting compassionate use, and established clinical infrastructure. The Asia-Pacific region is emerging rapidly, with countries like Georgia maintaining decades of clinical phage therapy experience and China and India expanding domestic research programs.

• •Human therapeutic applications, including chronic infections, wound care, and respiratory tract infections, account for the majority of market value and are projected to remain the primary growth segment
• •North America leads in market revenue due to FDA-approved clinical trials, while Europe maintains the largest network of operating phage therapy centers
• •The Asia-Pacific region is growing fastest, leveraging established phage therapy traditions in Georgia and expanding research capacity in China, India, and Australia

What are the recent trends and outlook?

The industry is shifting toward precision phage therapy using rapid diagnostic techniques to match phages to individual patients' infections, supported by expanding phage library databases and computational tools for phage selection. Synthetic biology and genetic engineering are enabling the development of phages with enhanced properties such as improved biofilm penetration, broader host ranges, and reduced immunogenicity. Ongoing and expanding clinical trials are expected to generate pivotal efficacy and safety data that could support broader regulatory approvals, potentially accelerating market growth as phage therapies move from compassionate-use scenarios toward standard-of-care protocols for resistant infections.

• •Artificial intelligence and machine learning are increasingly applied to phage-host matching, accelerating the personalized medicine approach that distinguishes phage therapy from conventional antibiotics
• •Engineered phages using CRISPR and synthetic biology modifications are entering clinical testing, offering advantages over naturally occurring phages in terms of safety profile and therapeutic efficacy
• •Manufacturing standardization efforts, including Good Manufacturing Practice-compliant production processes, are critical for regulatory approval and commercial scalability